Abstract
Long-acting injectable antipsychotics (LAIs) can lead to improved outcomes for people with schizophrenia, schizoaffective disorder, and bipolar disorder, as they guarantee medication delivery during the injection interval. Contemporary guidance on the use of LAIs includes considering not only patients with poor or uncertain adherence but also patients who would prefer monthly administration (or longer) of their maintenance medication, including those in their first episode of illness. This narrative review discusses the incorporation of LAIs in treatment planning across different settings: acute inpatient units, community mental health outpatient clinics, and jails. Implementing this treatment modality requires the recognition of eligible patients, providing information to patients and their families about the benefits and drawbacks of LAIs, and educating all members of the treatment team.